A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) (NCT06472076)
A Randomized, Multicenter, Double-blind, Phase 3 Study to Investigate the Safety and Efficacy of Belrestotug in Combination With Dostarlimab Compared With Placebo in Combination With Pembrolizumab in Participants With Previously Untreated, Unresectable, Locally Advanced or Metastatic PD-L1 Selected Non-small Cell Lung Cancer (GALAXIES Lung-301)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to evaluate the safety and tolerability profile of dostarlimab in combination with belrestotug when compared with pembrolizumab and placebo in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1 high NSCLC.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Ocala, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (108 Sites)
Showing the first 25 of 108 sites.
- GSK Investigational Site — Ocala, Florida
- GSK Investigational Site — Honolulu, Hawaii
- GSK Investigational Site — Lexington, Kentucky
- GSK Investigational Site — Lexington, Kentucky
- GSK Investigational Site — Omaha, Nebraska
- GSK Investigational Site — Nashville, Tennessee
- GSK Investigational Site — Fort Worth, Texas
- GSK Investigational Site — Olympia, Washington
- GSK Investigational Site — Buenos Aires,
- GSK Investigational Site — Cipoletti Rio Negro,
- GSK Investigational Site — Ciudad Autonoma de Buenos Aire,
- GSK Investigational Site — Ciudad Autonoma de Bueno,
- GSK Investigational Site — Córdoba,
- GSK Investigational Site — Florida,
- GSK Investigational Site — Mendoza,
- GSK Investigational Site — Rosario,
- GSK Investigational Site — San Miguel de Tucumán,
- GSK Investigational Site — Hasselt,
- GSK Investigational Site — Mont Gaston,
- GSK Investigational Site — Barretos,
- GSK Investigational Site — Belém,
- GSK Investigational Site — CuritibaPR,
- GSK Investigational Site — Florianópolis,
- GSK Investigational Site — Fortaleza,
- GSK Investigational Site — Londrina,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Cancer, Non-Small Cell
- A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer — Plantation, Florida
- Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy — Fountain Valley, California
- A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs — Dothan, Alabama
Explore by condition: All Lung Cancer, Non-Small Cell clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.